KATHERINE LEATHERMAN: Open Payments
NPI 1598122426 · EUGENE, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 36 payments from 9 companies in 2025. Trend: 2023 $444 · 2024 $360 · 2025 $766
Food & beverage: $766
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $253 |
| Otsuka America Pharmaceutical, Inc. | 9 | $182 |
| Axsome Therapeutics, Inc. | 3 | $86 |
| Collegium Pharmaceutical, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Lundbeck LLC | 1 | $28 |
| Neuronetics, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: VRAYLAR, REXULTI, Auvelity, Jornay PM, CAPLYTA, ABILIFY ASIMTUFII, TRINTELLIX, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across OR — which companies pay providers there.
